Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 6/2007

01-06-2007 | Article

Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy

Authors: M. García-Ramírez, F. Canals, C. Hernández, N. Colomé, C. Ferrer, E. Carrasco, J. García-Arumí, R. Simó

Published in: Diabetologia | Issue 6/2007

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to compare the protein profile of vitreous fluid from diabetic patients with proliferative diabetic retinopathy (PDR) with that from non-diabetic patients with idiopathic macular holes (MH). The mRNA of proteins differentially produced was also assessed in the retinas from diabetic and non-diabetic donors.

Materials and methods

Vitreous humour from type 1 diabetic patients with PDR (n = 8) and from non-diabetic patients with MH (n = 10) closely matched in terms of age were studied. The comparative proteomic analysis was performed using fluorescence-based difference gel electrophoresis (DIGE). Differentially produced proteins (abundance ratio >1.4, p < 0.05) were identified by mass spectrometry. Expressions of mRNA were measured by real-time RT-PCR in retinas from ten human eyes obtained at post-mortem (five eyes from diabetic subjects and five eyes from non-diabetic subjects).

Results

Eight proteins were highly produced in PDR patients in comparison with non-diabetic subjects: zinc-α2-glycoprotein (ZAG), apolipoprotein (apo) A1, apoH, fibrinogen A, and the complement factors C3, C4b, C9 and factor B). We found three proteins that were underproduced in PDR subjects: pigment epithelial derived factor (PEDF), interstitial retinol-binding protein (IRBP) and inter-α-trypsin inhibitor heavy chain (ITIH2). There was no overlap in the vitreous levels of the above-mentioned proteins between PDR patients and non-diabetic control subjects. The differential production of ZAG, C3, factor B, PEDF and IRBP was further confirmed by western blot, and was in agreement with mRNA levels detected in the retina.

Conclusions/interpretation

Proteomic analysis by DIGE, which permits an accurate quantitative comparison, was useful in identifying new potential candidates involved in the pathogenesis of PDR.
Appendix
Available only for authorised users
Literature
1.
Congdon N, Friedman DS, Lietman T (2003) Important causes of visual impairment in the world today. JAMA 290:2057–2060PubMedCrossRef
2.
Burgos R, Mateo C, Canton R, Hernandez C, Mesa J, Simo R (2000) Vitreous levels of IGF-1, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy. A case–control study. Diabetes Care 23:80–83PubMedCrossRef
3.
Simo R, Lecube A, Segura RM, Garcia-Arumi J, Hernandez C (2002) Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol 134:376–382PubMedCrossRef
4.
Simo R, Lecube A, Sararols L, Garcia-Arumi J, Segura RM, Hernandez C (2002) Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients. Diabetes Care 25:2282–2286PubMedCrossRef
5.
Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C (2006) Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diab Rev 2:71–98CrossRef
6.
Gorg A, Weiss W, Dunn MJ (2004) Current two-dimensional electrophoresis technology for proteomics. Proteomics 4:3666–3685
7.
Nakanishi T, Koyama R, Ikeda T, Shimizu A (2002) Catalogue of soluble proteins in the human vitreous humor: comparison between diabetic retinopathy and macular hole. J Chromatogr B Analyt Technol Biomed Life Sci 776:89–100PubMedCrossRef
8.
Koyama R, Nakanishi T, Ikeda T, Shizimu A (2003) Catalogue of soluble proteins in human vitreous humor by one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrospray ionization mass spectrometry including seven angiogenesis-regulating factors. J Chromatogr B Analyt Technol Biomed Life Sci 792:5–21PubMedCrossRef
9.
Yamane K, Minamoto A, Yamashita H et al (2003) Proteome analysis of human vitreous proteins. Mol Cell Proteomics 2:1177–1187PubMedCrossRef
10.
Wu CH, Sauter JL, Johnson PK, Chen CD, Olsen TW (2004) Identification and localization of major soluble vitreous proteins in human ocular tissue. Am J Ophthalmol 137:655–661PubMedCrossRef
11.
Ouchi M, West K, Crabb JW, Kinoshita S, Kamei M (2005) Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res 81:176–182PubMedCrossRef
12.
Wilson AS, Hobbs BG, Shen WY et al (2003) Argon laser photocoagulation-induced modification of gene expression in the retina. Invest Ophthalmol Vis Sci 44:1426–1434PubMedCrossRef
13.
Alban A, David SO, Bjorkesten L et al (2003) A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3:36–44PubMedCrossRef
14.
Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal Chem 68:850–858PubMedCrossRef
15.
Spranger J, Osterhoff M, Reimann M et al (2001) Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 50:2641–2645PubMedCrossRef
16.
Ogata N, Tombran-Tink J, Nishikawa M et al (2001) Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol 132:378–382PubMedCrossRef
17.
Cunnion KM, Hair PS, Buescher ES (2004) Cleavage of complement C3b to iC3b on the surface of Staphylococus aureus is mediated by serum complement factor I. Infect Immun 72:2858–2863PubMedCrossRef
18.
Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M (2000) Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol 12:1015–1023PubMedCrossRef
19.
Sanchez LM, Lopez-Otin C, Bjorkman PJ (1997) Biochemical characterization and crystalization of human Zn-alpha2-glycoprotein, a soluble class I major histocompatibility complex homolog. Proc Natl Acad Sci USA 94:4626–4630PubMedCrossRef
20.
Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsh M, Trayhurn P (2005) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579:41–47PubMedCrossRef
21.
Bing C, Bao Y, Jenkins J et al (2004) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci USA 101:2500–2505PubMedCrossRef
22.
Russell ST, Zimmerman TP, Domin BA, Tisdale MJ (2003) Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Biochim Biophys Acta 1636:59–68
23.
Gohda T, Makita Y, Shike T et al (2003) Identification of epistatic interaction involved in obesity using the KK/Ta mouse as a type 2 diabetes model: is Zn-alpha2 glycoprotein-1 a candidate gene for obesity? Diabetes 52:2175–2181PubMedCrossRef
24.
Gohda T, Tanimoto M, Shiina K et al (2004) Altered mouse cholinephosphotransferase gene expression in kidneys of type 2 diabetic KK/TA mouse. Metabolism 53:842–846PubMedCrossRef
25.
He N, Brysk H, Tyring SK, Ohkubo I, Brysk MM (2001) Zinc-alpha2-glycoprotein hinders cell proliferation and reduces Cdc2 expression. J Cell Biochem 81:162–169PubMedCrossRef
26.
Joussen AM, Poulaki V, Le ML et al (2004) A central role of inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450–1452PubMed
27.
Meleth AD, Agron E, Chan CC et al (2005) Serum inflammatory markers in diabetic retinopathy. Invest Opthalmol Vis Sci 46:4295–4301CrossRef
28.
Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R (2005) Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 22:710–722
29.
Zhang J, Gerhardinger C, Lorenzi M (2002) Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 51:3499–3504PubMedCrossRef
30.
Grisanti S, Wiedemann P, Weller M, Heimann K, Zilles K (1991) The significance of complement in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 32:2711–2717PubMed
31.
Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M (2004) Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 53:2404–2411PubMedCrossRef
32.
Barnstable CJ, Tombran-Tink J (2004) Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res 23:561–577PubMedCrossRef
33.
Dawson DW, Volpert OV, Gilis P et al (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–248PubMedCrossRef
34.
Ogata N, Tombran-Tink J, Jo N, Mrazek D, Matsumura M (2001) Upregulation of pigment epithelium-derived factor after laser photocoagulation. Am J Ophthalmol 132:427–429PubMedCrossRef
35.
Chader GJ (1989) Interphotoreceptor retinoid-binding protein (IRBP): a model protein for molecular biological and clinically relevant studies. Friedenwald lecture. Invest Ophthalmol Vis Sci 30:7–22PubMed
36.
Liou GI, Bridges CD, Fong SL, Alvarez RA, Gónzalez-Fernandez F (1982) Vitamin A transport between retina and pigment epithelium—an interstitial protein carrying endogenous retinol (interstitial retinol-binding protein). Vision Res 22:1457–1467PubMedCrossRef
37.
Pepperberg DR, Okajima TL, Wiggert B, Ripps H, Crouch RK, Chader GJ (1993) Interphotoreceptor retinoid-binding protein (IRBP). Molecular biology and physiological role in the visual cycle of rhodopsin. Mol Neurobiol 7:61–85PubMed
Metadata
Title
Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy
Authors
M. García-Ramírez
F. Canals
C. Hernández
N. Colomé
C. Ferrer
E. Carrasco
J. García-Arumí
R. Simó
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0627-y

Other articles of this Issue 6/2007

Diabetologia 6/2007 Go to the issue

Commentary

Can we out-run the diabetes epidemic?

Article

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

Short Communication

Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death

Short Communication

Intra-abdominal fat accumulation predicts the development of the metabolic syndrome in non-diabetic Japanese-Americans

Article

Enhanced activity of the myocardial Na+/H+ exchanger contributes to left ventricular hypertrophy in the Goto–Kakizaki rat model of type 2 diabetes: critical role of Akt

Article

Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits